Glaukos CFO Earns 3,660 Performance-Based Stock Options in Filing
Glaukos Corporation disclosed that its senior vice president and chief financial officer earned 3,660 stock options tied to performance goals.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
Glaukos Corporation disclosed that its senior vice president and chief financial officer earned 3,660 stock options tied to performance goals. These options, with an exercise price of $55.18 per share, are part of an award originally granted in March 2022 and became earned after the company met specified operational targets.
Half of this earned portion will vest and become exercisable in March 2026, with the remaining half vesting in December 2026. After this update and a de minimis correction of a prior mathematical error, the officer directly holds 37,510 stock options in total.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Stock Option (Right to Buy) | 3,660 | $0.00 | $0.00 |
Footnotes (3)
- F1. Represents a portion of an option to purchase shares of common stock previously granted by the Issuer on March 24, 2022, the vesting of which was subject to the Issuer's achievement of certain pre-determined operational targets over a multi-year performance period. The Compensation, Nominating & Governance Committee of the Issuer's Board of Directors determined that certain of the operational targets had been achieved. The number of shares of common stock subject to the stock option as reported herein consists of the portion of the award that was earned based upon the achievement of the operational targets.
- F2. 50% of the portion of the option reported herein will vest and become exercisable in March 2026. 50% of the portion of the option reported herein will vest and become exercisable in December 2026.
- F3. Amount reported reflects a de minimis adjustment to correct a mathematical error previously reported.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What insider transaction did Glaukos Corporation (GKOS) report in this filing?
What is the exercise price of the Glaukos (GKOS) stock options reported?
When do the Glaukos CFO’s performance-based options vest?
Are these Glaukos stock options a new grant or part of a prior award?
How many stock options does the Glaukos officer hold after this transaction?
Why was there a de minimis adjustment mentioned in the Glaukos (GKOS) filing?
AI-generated analysis. How Rhea-AI works. Not financial advice.